Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less

Japanese Journal of Ophthalmology

Volumn 55, Issue 6, 2011, Pages 605-613

  Nakano, Tadashi ^a   Yoshikawa, Keiji ^b   Kimura, Tairo ^c   Suzumura, Hirotaka ^d   Nanno, Mami ^e   Noro, Takahiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Yoshikawa Eye Clinic   (Japan)

^c Ueno Eye Clinic   (Japan)

^d Nakano General Hospital   (Japan)

^e Nihonmatsu Eye Hospital   (Japan)

Author keywords

Adverse drug reaction; Adverse event; Intraocular pressure reduction; Normal tension glaucoma; Tafluprost

Indexed keywords

LEUPRORELIN; TAFLUPROST;

ABNORMAL SENSATION; ADULT; ADVERSE OUTCOME; ARTICLE; ASTHENOPIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE IRRITATION; EYELID DISEASE; FEMALE; HUMAN; HYPEREMIA; INCIDENCE; INTRAOCULAR PRESSURE; IRIS DISEASE; LOW TENSION GLAUCOMA; MALE; MULTICENTER STUDY; PIGMENT DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F; TONOMETRY, OCULAR; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 82955247821     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-011-0082-7     Document Type: Article

References (25)

1. T Yamamoto A Iwase M Araie Y Suzuki H Abe S Shirato, et al. 2005 The Tajimi Study report 2 Ophthalmology 112 1661 1669 16111758 10.1016/j.ophtha. 2005.05.012 (Pubitemid 41400000)
2. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
3. Japan Glaucoma Society. The Japan glaucoma society guidelines for glaucoma (2nd edition). Nippon Ganka Gakkai Zasshi. 2006;110:777-814.
4. G Tomita M Araie Y Kitazawa S Tsukahara 2004 A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients Eye (London) 18 984 989 10.1038/sj.eye.6701373 1:CAS:528:DC%2BD2cXotFWns7w%3D (Pubitemid 39430034)
5. N Kondo A Sawada T Yamamoto T Taniguchi 2006 Correlation between individual differences in intraocular pressure reduction and outflow facility due to latanoprost in normal-tension glaucoma patients Jpn J Ophthalmol 50 20 24 16453183 10.1007/s10384-005-0267-z (Pubitemid 43201029)
6. GS Ang JP Kersey L Shepstone DC Broadway 2008 The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial Br J Ophthalmol 92 1129 1133 18511540 10.1136/bjo.2007.135269 1:STN:280:DC%2BD1cvntlakuw%3D%3D
7. 2α derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents Biol Pharm Bull 26 1691 1695 14646172 10.1248/bpb.26.1691 1:CAS:528:DC%2BD3sXpvFaksro%3D (Pubitemid 39663527)
8. Y Takagi T Nakajima A Shimazaki M Kageyama T Matsugi Y Matsumura, et al. 2004 Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug Exp Eye Res 78 767 776 15037111 10.1016/j.exer.2003.12.007 1:CAS:528:DC%2BD2cXhsV2gtr8%3D (Pubitemid 38252953)
9. Kuwayama Y, Komemushi S. Phase III confirmatory study of 0.0015% DE-085(tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka. 2008;25:1595-602 (in Japanese).
10. H Uusitalo LE Pillunat A Ropo On Behalf of the Phase III Study Investigators 2010 Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study Acta Ophthalmol 88 12 19 20420586 10.1111/j.1755-3768.2010.01862.x 1:CAS:528:DC%2BC3cXjs1Grtbg%3D
11. CE Traverso A Ropo M Papadia H Uusitalo 2010 A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost J Ocul Pharmacol Ther 26 97 104 20148656 10.1089/jop.2009.0066 1:CAS:528:DC%2BC3cXjsFaksLc%3D
12. E Egorov A Ropo On Behalf of the Investigators 2009 Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma Eur J Ophthalmol 19 214 222 19253237
13. Kuwayama Y, Komemushi S. Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study. Nippon Ganka Gakkai Zasshi. 2010;114:436-43 (in Japanese).
14. A Iwase Y Suzuki M Araie T Yamamoto H Abe S Shirato, et al. 2004 The prevalence of primary open-angle glaucoma in Japanese, The Tajimi Study Ophthalmology 111 1641 1648 15350316 (Pubitemid 39179676)
15. S Yamazaki M Nanno T Kimura H Suzumura K Yoshikawa 2010 Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost Jpn J Ophthalmol 54 7 14 20151269 10.1007/s10384-009-0754-8
16. MB Ahmed GH William 2003 One-minute Schirmer test with anesthesia Cornea 22 285 287 10.1097/00003226-200305000-00001 (Pubitemid 36578522)
17. MH Suh KH Park DM Kim 2009 Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma Jpn J Ophthalmol 53 18 23 19184304 10.1007/s10384-008-0617-8
18. D Kjellgren G Douglas FS Mikelberg SM Drance A Alm 1995 The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma Acta Ophthalmol Scand 73 233 236 7493234 10.1111/j.1600-0420.1995.tb00274.x 1:STN:280:DyaK287hsFSgtA%3D%3D
19. M Mckibbin MJ Menage 1999 The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma Eye 13 31 34 10396380 10.1038/eye.1999.6 (Pubitemid 29121594)
20. Y Ikeda K Mori T Ishibashi S Naruse N Nakajima S Kinoshita 2006 Latanoprost nonresponders with open-angle glaucoma in the Japanese population Jpn J Ophthalmol 50 153 157 16604392 10.1007/s10384-005-0293-x 1:CAS:528:DC%2BD28XktFaqsr0%3D
21. L Rossetti S Gandolfi C Traverso P Montanari M Uva G Manni, et al. 2006 An evaluation of the rate of nonresponders to latanoprost therapy J Glaucoma 15 238 243 16778647 10.1097/01.ijg.0000212214.18018.41
22. TJ Zimmerman WC Stewart Latanoprost Axis Study Group 2003 Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments J Ocul Pharmacol Ther 19 405 415 14583133 10.1089/108076803322472971 1:CAS:528:DC%2BD3sXotFCmtrs%3D (Pubitemid 37321343)
23. Kitazawa Y, Latanoprost Study Group. An open-label multicenter study on the efficacy and safety of topical use of latanoprost for 156 weeks. Rinsho Ganka (Jpn J Clin Ophthalmol). 2006;60:2047-54 (in Japanese). (Pubitemid 46154247)
24. F Honrubia J Garacia-Sanchez V Polo JM Martinez de la Casa J Soto 2009 Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials Br J Ophthalmol 93 316 321 19019922 10.1136/bjo.2007.135111 1:STN:280:DC%2BD1M7msFChsA%3D%3D
25. P Denis C Baudouin A Bron JP Nordmann JP Renard JF Rouland, et al. 2010 First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure BMC Ophthalmol 10 4 20181282 10.1186/1471-2415-10-4